Drug Trial Radar · NCT05038592
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Mar 4, 2022
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tagraxofusp and decitabine may help to control the disease in patients with chronic myelomonocytic leukemia.
Conditions
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Myelodysplastic/Myeloproliferative Neoplasm
Interventions
DecitabineDrug
Given IV
Tagraxofusp-erzsBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerable dose (Phase I)Time frame: At end of cycle 1 (1 cycle = 28 days)
- Incidence of dose limiting toxicities (Phase I)Time frame: Up to end of cycle 1 (1 cycle = 28 days)
- Overall response (OR) (Phase II)Time frame: After 2 cycles of therapy (1 cycle = 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.